Mesoblast Limited (Mesoblast) is engaged in the principal activity of developing bio-therapeutics based on its cell-based and protein technologies. Mesoblast’s cell-based core technologies include its immunoselected Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs).
© Data powered by Morningstar, Inc. 2023. All rights reserved.
Neither Morningstar, its affiliates, nor the content providers guarantee the
market indices, commodities and regulatory news headlines, and other data or
content contained herein to be accurate, complete, or timely, and nor shall
they have any liability for its use or distribution. The data contained
herein: (1) is proprietary to Morningstar and/or its affiliates
(collectively, “Morningstar”) and/or their content providers; (2) may not be
copied or distributed; and (3) is not warranted to be accurate, complete, or
timely. Our publications, ratings and products should be viewed as an
additional investment resource, and not as your sole source of information.
Past performance does not necessarily indicate a financial product’s future
performance. To obtain advice tailored to your financial situation, contact
a professional financial adviser. Some material is copyrighted and published
under licence from ASX Operations Pty. Ltd. ACN 004523782.